Unlock stock picks and a broker-level newsfeed that powers Wall Street.
2,625.35
-121.63
(-4.43%)
At close: April 4 at 1:54:06 PM CST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 23 | 21 | 36 | 35 |
| Avg. Estimate | 863.11M | 1.29B | 5.51B | 6.61B |
| Low Estimate | 796.5M | 1.06B | 5.27B | 5.96B |
| High Estimate | 1.25B | 1.56B | 5.72B | 7.2B |
| Year Ago Sales | 794.11M | 1.01B | 4.21B | 5.51B |
| Sales Growth (year/est) | 8.69% | 27.76% | 30.97% | 20.06% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| FSLR.MX | -- | -- | -- | -- |
| S&P 500 | 6.57% | 6.54% | 9.73% | 14.28% |
Upgrades & Downgrades
| Reiterates | Truist Securities: Buy to Buy | 4/2/2025 |
| Maintains | Barclays: Overweight to Overweight | 2/28/2025 |
| Maintains | Guggenheim: Buy to Buy | 2/27/2025 |
| Maintains | Morgan Stanley: Overweight to Overweight | 2/27/2025 |
| Maintains | UBS: Buy to Buy | 2/26/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 2/26/2025 |